Methotrexate in atopic eczema – Reply to a letter

Abstract

Goujon et al. submit a letter‐type manuscript to JEADV (1), as a comment to the recently published European consensus‐based S2k guidelines or treatment of atopic eczema (2,3). The assigned writing subgroups for each topic were encouraged to include the 'best available evidence' for all chapters of the guideline (2). Data were included only if a reference had been published as a full paper in a peer‐reviewed journal by March 2017 (see page 661 of the guideline), but not based on an abstract or a conference presentation only (2).

This article is protected by copyright. All rights reserved.

https://ift.tt/2E5YvMy